CytomX Therapeutics Inc in the state of Delaware in September 2010. The Company is an oncology-focused biopharmaceutical company pioneering antibody therapeutics based on its Probody technology platform. It is using its platform to create proprietary cancer immunotherapies against clinically-validated targets as well as to develop cancer therapeutics against novel targets. The Company is engaged in developing Probody therapeutics that address clinically-validated cancer targets in immuno-oncology, such as PD-L1, as well as targets, such as CD-166. The Company competes with biopharmaceutical companies, specialty biotechnology companies, academic research departments and public and private research institutions. Governmental authorities in the U.S., at the federal, state and local level and other countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, packaging, promotion, storage, advertising, distribution, marketing and export and import of products such as those it is developing.
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.